NCT07287904Not yet recruiting
Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
A Retrospective Analysis Study on Predicting the Efficacy of Targeted Therapy in Lung Cancer Patients With EGFR Mutations Based on AI-driven Multimodal Data
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 24 Nov 2025
- Start date
- Dec 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Lung cancer
- NCT number
- NCT07287904
What you commit to
- Study type: Observational
- Planned participants: 1000
- From Dec 2025 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Incomplete surgical resection (R1, R2);
- Patients who died within 30 days post-surgery.
Lab values
- Patients negative for EGFR;
- Did not receive EGFR-TKI targeted therapy after surgery;
Other
- Recurrent or advanced stage patients;
- Incomplete preoperative or postoperative data;
Who the study is looking for
- Age 18-80 years, undergoing radical surgery for lung cancer (R0 resection);
- Postoperative pathological stage IB-IIIA, pathology confirmed as adenocarcinoma;
- EGFR gene testing positive, EGFR 19del/L858R mutation;
- Receiving postoperative EGFR-TKI targeted adjuvant therapy;
- Complete and clear preoperative imaging data, genetic testing report, and pathology report available.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wuhan Union Hospital Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.